Navigation Links
BioMarin Initiates Phase 1 Trial for BMN 673 in Patients With Advanced Hematological Malignancies
Date:7/14/2011

NOVATO, Calif., July 14, 2011 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) today announced the initiation of a Phase 1 trial for BMN 673, a poly ADP-ribose polymerase (PARP) inhibitor, for the treatment of patients with advanced hematological malignancies.  A Phase 1/2 trial for BMN 673 for the treatment of patients with solid tumors was initiated in January 2011 and is ongoing.

"We are excited to be at the forefront of studying the potential benefit of PARP inhibitors in hematological malignancies," said Hank Fuchs, M.D., Chief Medical Officer of BioMarin.  "Our approach to the development of our PARP inhibitor is to identify tumor mutations that are more susceptible to treatment with BMN 673 and to target subgroups based on the genetic basis of the disease.  We are committed to the advancement of our pipeline and look forward to many clinical milestones over the next 18 months."

This Phase 1 trial is a two-arm, open-label dose escalation study to determine the maximum tolerated dose and to assess the safety, pharmacokinetics, pharmacodynamics and preliminary efficacy of once daily, oral BMN 673 in patients with acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), chronic lymphocytic leukemia (CLL) or mantle cell lymphoma (MCL).  The study will enroll approximately 80 patients across multiple sites in the U.S. and UK.

About BioMarinBioMarin develops and commercializes innovative biopharmaceuticals for serious diseases and medical conditions. The company's product portfolio comprises four approved products and multiple clinical and pre-clinical product candidates. Approved products include Naglazyme® (galsulfase) for mucopolysaccharidosis VI (MPS VI), a product wholly developed and commercialized by BioMarin; Aldurazyme® (laronidase) for mucopolysaccharidosis I (MPS I), a product which BioMarin developed
'/>"/>

SOURCE BioMarin Pharmaceutical Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. BioMarin Announces Roll-Out of National PKU Registry
2. BioMarin to Present at the Citi Biotech Day
3. BioMarin to Present at the Morgan Stanley Global Healthcare Conference
4. BioMarin to Present at the Merrill Lynch Global Pharmaceutical Conference
5. BioMarin Corrects Information Included in Bloomberg Article
6. BioMarin Announces Third Quarter 2008 Financial Results
7. BioMarin to Present at the Credit Suisse Healthcare Conference
8. BioMarin Announces the Planned Retirement of Dr. Emil Kakkis, Chief Medical Officer
9. BioMarin to Present at the Piper Jaffray Healthcare Conference
10. BioMarin to Host Fourth Quarter and Full Year 2008 Financial Results Conference Call and Webcast on Wednesday, February 18 at 5:00 p.m. ET (23:00 CET)
11. BioMarin Announces Fourth Quarter and Full Year 2008 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/21/2014)... 21, 2014  BioSpecifics Technologies Corp. (NASDAQ: ... in class collagenase-based products marketed as XIAFLEX ® ... U.S. and XIAPEX ® in the EU, ... randomized, double-blind Phase 2a study of CCH for ... panniculopathy. The results showed that all three doses ...
(Date:8/21/2014)... Rockville, MD (PRWEB) August 21, 2014 ... is making progress in its development of JRC-LAMP-vax, an ... red cedar pollen. Phase IC studies began this month ... solution to hay fever. , The Japanese red cedar ... million people in Japan. Mountain Cedar pollen wreaks similar ...
(Date:8/21/2014)... the Institute for Molecular Medicine Finland (FIMM), University ... a novel "man and machine" decision support system ... was described in PLOS One scientific ... on computer vision algorithms similar to those used ... only the diagnostically most relevant areas. Tablet computers ...
(Date:8/21/2014)... has observed tiny quantum vortices in cold droplets of ... Science that the exotic vortices arrange themselves as ... first time that the quantum vortices, which have already ... as superfluid helium, have been detected in nanodroplets. "The ... of the University of Southern California, one of the ...
Breaking Biology Technology:BioSpecifics Technologies Corp. Announces Positive Data from Phase 2a Study of CCH for Treatment of Cellulite 2BioSpecifics Technologies Corp. Announces Positive Data from Phase 2a Study of CCH for Treatment of Cellulite 3BioSpecifics Technologies Corp. Announces Positive Data from Phase 2a Study of CCH for Treatment of Cellulite 4BioSpecifics Technologies Corp. Announces Positive Data from Phase 2a Study of CCH for Treatment of Cellulite 5Relief for Allergy Sufferers Finally in Sight: Immunomic Therapeutics Closes in on Treatment for Hay Fever in Japan, U.S. 2Relief for Allergy Sufferers Finally in Sight: Immunomic Therapeutics Closes in on Treatment for Hay Fever in Japan, U.S. 3Relief for Allergy Sufferers Finally in Sight: Immunomic Therapeutics Closes in on Treatment for Hay Fever in Japan, U.S. 4A novel 'man and machine' decision support system makes malaria diagnostics more effective 2Scientists observe quantum vortices in cold helium droplets 2
... develop a more robust information technology industry, Wisconsin may ... at this week's E-Business Best Practices and Emerging Technologies ... notably RedPrairie's John Jazwiec, have not been ... attending the annual E-Business conference did not cite Jazwiec's ...
... more than a year-long "break" in Iraq, Matt Storms is ... His previous columns covered due diligence and corporate clean up, ... (SBIR) and Small Business Technology Transfer (STTR) grants. We thank ... following advice to Wisconsin entrepreneurs. , , Once ...
... Madison-based Imago Scientific Instruments has sold one ... College of Engineering for use in the new ... ,The lab will be the primary research center of ... Balaji Narasimhan, an associate professor of chemical and biological ...
Cached Biology Technology:To drive IT, Wisconsin may need entrepreneurial makeover 2To drive IT, Wisconsin may need entrepreneurial makeover 3Raising capital through placement agents 2Raising capital through placement agents 3Raising capital through placement agents 4
(Date:8/21/2014)... including researchers from the University of Georgia recently published the ... journal Science . Their discovery paves the way for ... farming and industry. , Canola is grown across much ... is increasingly cultivated in Georgia. Canola oil used for cooking ... and rich supply of omega-3 fatty acids, but the plant ...
(Date:8/21/2014)... a significant reduction in smog-producing toxins in past ... A new study shows that while the Greater ... the toxins that contribute to smog, the city ... air pollution., Smog, which can cause or aggravate ... bronchitis, is produced by a set of complex ...
(Date:8/21/2014)... study of American singles found that during sex ... orgasm rates. On average, men experience orgasm 85.1 ... making little difference. For women, however, orgasm occurrence ... 62.9 percent of the time during sex with ... with women,s sexual orientation, with lesbian women experiencing ...
Breaking Biology News(10 mins):Canola genome sequence reveals evolutionary 'love triangle' 2Despite a significant reduction in smog-producing toxins, the Greater Toronto Area still violates Canada's standards for ozone air pollution 2Orgasm rates for single women less predictable than men's, vary by sexual orientation 2Orgasm rates for single women less predictable than men's, vary by sexual orientation 3Orgasm rates for single women less predictable than men's, vary by sexual orientation 4
... to the dinosaurs, and he or she will likely tell ... dinosaurs rose to prominence and you,ll likely get a blank ... the subject. But now, as EARTH explores in a feature ... backstory of the rise of dinosaurs. Learn more about ...
... CHAMPAIGN, Ill. Researchers have determined the structure and ... step in the formation of cholesterol and a key ... University of Illinois and collaborators in Taiwan studied a ... and many bacteria that begins the synthesis of triterpenes ...
... Soy protein,s ability to lower total and LDL ... extensively studied, but the mechanism whereby soy protein ... in the Journal of Clinical Lipidology ... cholesterol and non-HDL (non-high-density lipoprotein) cholesterol significantly more ...
Cached Biology News:Chemists document workings of key staph enzyme -- and how to block it 2New study shows soy protein lowers non-HDL cholesterol significantly more than milk protein 2
Rat monoclonal [20d5] to NKG2A + C+ E ( Abpromise for all tested applications). Antigen: Tissue / cell preparation (Mouse): CHO transfected cells expressing the B6 allele of NKG2A. Entrez Gen...
... Fluoroskan Ascent FL ... fluorometric and luminometric measurement ... long list of advanced ... and Luminoskan Ascent. Fluoroskan ...
... stainless steel rack holders ... mechanism that permits selection ... angles, and "snap-in" product ... rack holder will accomodate ...
... The dotLab System brings together two ... and immobilized capture surfaces. This combination ... technique for the detection of molecular ... fluorescent labels. , Protein-specific capture molecules ...
Biology Products: